Investigational agent Zelicapavir cut time to complete RSV symptom resolution by up to a week and lowered hospitalization in high-risk adults.
|Articles|September 9, 2020
An Interview on the First US Double Lung Transplant for COVID-19
Author(s)Kevin Kunzmann
How a Chicago-based surgeon managed an unprecedented procedure for young woman at the height of the pandemic.
Advertisement
The greatest headlines of
With an act that saved just one life, though, Ankit Bharat, MD, delivered a historic win for the state of COVID-19 care and capabilities.
In May, the chief of thoracic surgery and surgical director of the Northwestern Medicine Lung Transplant Program performed the first double lung transplant for a critically ill COVID-19 patient in the US.
The patient—a young, healthy Hispanic women—had little to not therapeutic options remaining as her lungs began to fail. Without precedence among his national peers and with intensive care cases skyrocketing in the Chicago area, Bharat’s team found a solution for her.
In this, the second ever episode of Lungcast from HCPLive® and the American Lung Association (ALA), Bharat talked with ALA Chief Medical Officer Al Rizzo, MD, about the groundbreaking procedure and its contribution to developing COVID-19 care and research.
He also gave perspective on the current and evolving role of thoracic surgery, the benefit of extracorporeal membrane oxygenation (ECMO) in his work, and the need for innovation in invasive lung care.
Subscribe or listen to Lungcast on your favorite platforms:
- Spotify: https://open.spotify.com/show/1F3u1hKrwxi9snSQ0q3nti
- Apple Podcasts: https://podcasts.apple.com/us/podcast/lungcast/id1524712350
Advertisement
Related to this article
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Oral zelicapavir cut time to complete RSV symptom resolution by up to 1 week in high-risk adults, but it did not meet its primary end point in a phase 2 trial.
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.
A 39-year-old unvaccinated Franklin County woman has died after a recent measles diagnosis. Nationally, numbers continue to increase and the US has passed 4,000 cases.
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
Advertisement
Advertisement